NCT04398524 2024-01-16A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPCISA PharmaceuticalsPhase 2 Unknown65 enrolled
NCT03669718 2023-12-29A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPCISA PharmaceuticalsPhase 2 Unknown194 enrolled
NCT05094804 2023-11-02A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsOncoResponse, Inc.Phase 1/2 Unknown172 enrolled